6IRA.F IRLAB THERAP. AB A
- Market cap
- EUR 29.5M
- P/E
- -
- P/B
- 3.14x
- ROE
- -20.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6IRA.F undervalued?
Graham numberThe Graham number of IRLAB THERAP. AB A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IRLAB THERAP. AB A fundamental analysis
No fundamental analysis for IRLAB THERAP. AB A yet.
IRLAB THERAP. AB A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IRLAB THERAP. AB A
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of fa…
Full company profileIRLAB THERAP. AB A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IRLAB THERAP. AB A annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 208M | 61.1M | 5.68M | 94.6M | 57.5M | 91.5M |
| Gross Profit | 169M | 61.1M | - | - | - | - |
| Operating Income | 52.5M | -113M | -181M | -74.6M | -87.0M | -12.0M |
| EBITDA | - | -108M | -173M | -68.1M | -84.5M | -6.70M |
| Net Income | 51.8M | -113M | -178M | -83.1M | -110M | -20.2M |
| EPS | 0.94 | -2.06 | -3.17 | -1.51 | -1.30 | -0.24 |
| Balance Sheet | ||||||
| Total Assets | 472M | 324M | 177M | 136M | 138M | 182M |
| Total Liabilities | 73.0M | 32.7M | 61.4M | 104M | 107M | 85.2M |
| Shareholders' Equity | 399M | 291M | 116M | 32.6M | 30.7M | 97.1M |
| Cash & Short-term Investments | 402M | 253M | 111M | 66.9M | 81.9M | 34.2M |
| Cash Flow | ||||||
| Operating Cash Flow | 129M | -143M | -165M | -65.6M | -55.2M | -84.2M |
| Capital Expenditure | 708K | 3.38M | 293K | 199K | 0.00 | 0.00 |
| Free Cash Flow | 128M | -146M | -165M | -65.8M | -55.2M | -84.2M |
| Ratios | ||||||
| ROE | 13.0% | -39.0% | -153.6% | -254.7% | -358.1% | -20.8% |
| ROA | 11.0% | -35.0% | -100.4% | -61.0% | -79.6% | -11.1% |
| Net Profit Margin | 24.9% | -185.5% | -3,132.1% | -87.8% | -191.4% | -22.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
IRLAB THERAP. AB A dividends
IRLAB THERAP. AB A has not paid dividends in the last 5 fiscal years.
Who owns IRLAB THERAP. AB A
- Insiders 16.27%
- Institutions 23.57%
- Public & others 60.16%
- Shares outstanding 149M
- Free float 122M
IRLAB THERAP. AB A company profile
- Company name
- IRLAB THERAP. AB A
- Ticker
- 6IRA.F
- ISIN
- SE0012675361
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 31
- Fiscal year end
- December
- Address
- Arvid Wallgrens Backe 20, Gothenburg, Sweden, 413 46
- Phone
- 46 3 17 57 38 00
- Website
- irlab.se
About IRLAB THERAP. AB A
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson's disease, and in a Phase IIA clinical trial for dementia in Parkinson's disease; and IRL757, which is in a Phase I clinical trial for the treatment of apathy in Parkinson's and other neurological disorders. It is also developing products in the preclinical stage, such as IRL942, an oral tablet for the treatment of cognitive deficits in Parkinson's and other neurological disorders; and IRL1117, an oral treatment for the hallmark symptoms of Parkinson's. In addition, the company develops P003, a research project that discovers and develops dopamine D1 and D2 receptor agonist compounds for the treatment of Parkinson's core motor symptoms. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
IRLAB THERAP. AB A management
6- Dr. Kristina Torfgard Ph.D.Chief Executive Officer · born 1963
- Mr. Gustaf Albèrt M.Sc.Chief Financial Officer · born 1968
- Dr. Peder Svensson Ph.D.Chief Information Officer and Director of Computational Chemistry & Biology · born 1962
- Ms. Cecilia Tivert Stenberg B.Sc.Head of Finance & Human Resource and Director of Accounting & Human Resources · born 1957
- Dr. Nicholas Waters Ph.D.Executive VP and Head of R&D · born 1962
- Dr. Joakim Tedroff M.D., Ph.D.Chief Medical Officer · born 1961